Medication info
Hugliya Tablet 25 mg (Sitagliptin Hydrochloride Hydrate)

Hugliya Tablet 25 mg (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›28.34mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Bright yellow-orange round film-coated tablet
Packaging
100 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202102408 · Approved 2021.03.17 · Insurance code 670609000

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes. It is used as an adjunct to diet and exercise therapy and can also be taken alone. If patients have not previously taken diabetes medications or have difficulty controlling blood sugar with monotherapy, it may be taken together with metformin. Additionally, in cases where treatment with sulfonylureas, metformin, thiazolidinediones, or insulin alone is insufficient, this medication can be combined to enhance blood sugar control. It may also be used additionally for patients who have difficulty controlling blood sugar with various drug combinations. This medication aids in improving blood sugar control in various therapeutic scenarios.

How to take

Adult dose

This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Precautions

This medication may cause severe allergic reactions after administration, so if symptoms such as skin rashes or breathing difficulties occur, it should be discontinued immediately and medical advice should be sought. There is also a risk of serious pancreatic inflammation known as pancreatitis, so if symptoms such as abdominal pain, nausea, or vomiting appear, it is important to visit a hospital quickly. This medication should not be used in patients with type 1 diabetes or those who have specific allergic reactions. Patients with impaired kidney function may experience drug accumulation in the body; therefore, dosage adjustment or cautious use is necessary, and periodic kidney function tests are recommended. Due to the risk of hypoglycemia, caution should be exercised when taking it with other antidiabetic agents like insulin or sulfonylureas, and dosage adjustments may be necessary if required. Severe joint pain or skin blistering has been reported on rare occasions; if such symptoms occur, contact a doctor immediately. It is recommended that pregnant or breastfeeding women do not take this medication, and safety has not been established in children under 18 years of age. In the case of overdose, appropriate treatment should be initiated, such as gastrointestinal decontamination and cardiac monitoring, and blood dialysis may be conducted if necessary to remove some of the medication.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory tract infections
  • nasopharyngitis
  • headache
  • diarrhea
Show 29 more
  • abdominal pain
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • arthritis with severe and disability
  • blistering dermatitis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air or moisture. It is also important to avoid excessively hot or cold places, and it is best to store it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Bright yellow-orange round film-coated tablet

Package unit

100 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.